OBJECTIVES: Novel combination therapies can improve survival compared with chemotherapy alone in patients with advanced NSCLC. However, acceptable tolera-py alone in patients with advanced NSCLC. However, acceptable tolera-n patients with advanced NSCLC. However, acceptable tolera-advanced NSCLC. However, acceptable tolerability is also important as it affects clinical outcomes, quality of life, and overall cancer treatment costs. This analysis assesses direct medical costs for the management of grade 3/4 adverse events (AEs) associated with two non-chemotherapies for first-line treatment of NSCLC consisting of either Bevacizumab (BEV) plus chemotherapy (CT) or Cetuximab (C) plus cisplatin/vinorelbine (CV). METHODS: Information on AE profiles were retrieved from the AVAiL study (7.5 mg/kg, Reck et al. 2009) and the mg/kg, Reck et al. 2009) and the mg/kg, Reck et al. 2009) and the E4599 study (15 mg/kg, Sandler et al. 2006) for BEV mg/kg, Sandler et al. 2006) for BEV mg/kg, Sandler et al. 2006) for BEV CT and from the FLEX study (Pirker et al. 2009) for C CV. To account for the inclusion of ECOG 2 patients in FLEX (which were excluded in AVAiL and E4599), incidences of febrile neutropenia, non-febrile neutropenia and leukopenia in FLEX were decreased by up to 30% based on expert suggestion to improve study comparability. Information on standard treatment patterns of the different AEs was collected through a systematic literature search and complemented by data provided by two German oncologists. These resource use items were assigned unit costs (charges) applicable to Germany. RESULTS: When unadjusted incidences of all AEs reported in AVAiL, E4599, and FLEX are used, resulting overall per-patient treatment costs related to the two BEV CT studies are substantially lower those related to C CV (a1092 and a464 versus a2287). Sensitivity analyses provide evidence that overall AE costs remain lower for AVAiL and E4599 even when incidences for selected AEs affected by cetuximab therapy are reduced by 10%, 20%, and 30% (a2151, a2015, and a1879, respectively). CONCLUSIONS: BEV CT shows better tolerability linked with lower AE treatment costs when compared to C CV. These favorable outcomes for BEV CT were maintained when AE frequencies for C CV were adjusted for ECOG status.
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Thoraxklinik Heidelberg, Heidelberg, Germany, 2 Krankenhaus Grosshansdorf, Grosshansdorf, Germany, 3 Outcomes International, Basel, Switzerland, 4 F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland OBJECTIVES: Novel combination therapies can improve survival as compared to ovel combination therapies can improve survival as compared to chemotherapy alone in patients with advanced NSCLC. Essential is also that these n patients with advanced NSCLC. Essential is also that these advanced NSCLC. Essential is also that these new therapies have acceptable tolerability profiles. Furthermore, toxicities can result in potentially high additional treatment costs. This analysis therefore aims to explore overall costs of adverse events (AEs) associated with two new biologics in first-line NSCLC consisting of either Bevacizumab (BEV) combined with chemotherapy (CT) or Cetuximab (C) combined with cisplatin vinorelbine (CV). METHODS: All published AEs and their incidences as reported in the AVAiL study (7.5 . 2006) were considered for BEV CT, whereas AE data for C CV was taken from the FLEX study (Pirker et al. 2009 ). A systematic literature search was performed to collect published information on standard treatment patterns and costs of AEs. To complement and further substantiate these results, two oncologists in Germany were interviewed to obtain additional information on medical resource utilization for the AEs considered. These resource use items were then assigned unit costs (charges) reflective of the German health care system. A spreadsheet model was used to calculate total average per-patient AE costs for the two compared therapy regimens. RESULTS: Our analysis shows substantially lower overall per-patient treatment costs for the grade 3/4 AE profiles specified in both BEV NSCLC trials (AVAiL and E4599) than for all severe AEs observed in the FLEX trial (a1092 and a464 versus a2287). The differences favouring BEV CT are mainly due to lower incidences of febrile neutropenia, leukopenia, neutropenia, sepsis, and anaemia than observed for a C CV regimen. CONCLUSIONS: BEV CT shows better tolerability and lower AE treatment costs as compared to C CV. Coupled with its favorable effectiveness, BEV CT should be considered as therapy of choice for patients with advanced NSCLC.
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COST OF CARE FOR COLORECTAL CANCER IN IRELAND: A HEALTH CARE PAYER PERSPECTIVE
Tilson L 1 , Sharp L 2 , Walsh C 3 , O'Ceilleachair A 2 , Usher C 1 , Comber H 2 , Barry M 1 1 National Centre for Pharmacoeconomics, Dublin, Ireland, 2 National Cancer Registry of Ireland, Cork, Ireland, 3 Trinity College Dublin, Dublin, Ireland OBJECTIVES: To estimate the average lifetime cost of care for patients with colorectal cancer in Ireland, from the perspective of the health care payer (HSE). METHODS: A decision tree model was developed in Microsoft Excel. Treatment pathways were constructed for each stage of colon cancer (CC) and rectal cancer (RC) from guidelines and expert clinical opinion. Healthcare resource use associated with diagnosis, treatment and follow-up were obtained from the National Cancer Registry (n 1,498; 36% RC and 64% CC; [2004] [2005] , and two local hospital databases (n 155 and 142; 2007) . Unit costs for hospitalisation, procedures, laboratory tests and radiotherapy were derived from DRG costs, hospital finance departments, clinical opinion and literature review. Chemotherapy costs were estimated from local hospital protocols, pharmacy department and clinical opinion. Future costs of follow-up were discounted at 4% over 5 years. Uncertainty was explored using one-way sensitivity analysis. RESULTS: Average lifetime costs per patient were higher for RC (Stage I a24,089; Stage II a40,950; Stage III a49,987; Stage IV a45,237) than CC (Stage I a23,462; Stage II a35,059; Stage III a48,186; Stage IV a31,774). Cost estimates were most sensitive to recurrence rates and prescribing of the biologic agents bevacizumab and cetuximab. CONCLUSIONS: This study demonstrates how costs of managing cancer can be estimated using existing data from national and local databases. The findings illustrate the major impact that the new biologic agents have on the cost of cancer care. They also highlight the potential to reduce health care resource utilisation by implementing strategies to detect colorectal cancer at earlier stages.
